Brief: EQL Pharma Jan-March EBITDA Swings To Loss Of SEK 602,000

EQL Pharma AB

23/05/2018 08:02

May 23 (Reuters) - EQL PHARMA AB  EQL.TE :
    * ESTIMATE THAT SALES FOR 2018/2019 FISCAL YEAR WILL BE MORE
THAN
30% HIGHER THAN COMPARABLE PERIOD - APRIL 2017 TO MARCH 2018.
    * JAN-MARCH GROSS PROFIT FOR QUARTER AMOUNTED TO SEK 3.7
(4.1)
MILLION, A DECREASE OF 9%
    * JAN-MARCH EBITDA LOSS SEK 602,000 VERSUS PROFIT SEK
339,000 YEAR
AGO

Source text for Eikon:  ID:nWkr3TkM9Z 
Further company coverage:  EQL.TE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))